... global clinical trials of SKL15508 this year. Expansion into other cognitive impairment disorders, such as Alzheimer's disease, is under consideration by the company. Dr. Christopher Gallen, CEO and President of SK Biopharmaceuticals, said, "This is ...
http://www.news-medical.net/news/20130418/FDA-authorizes-SK-Biopharmaceuticals-IND-application-for-SKL15508-to-treat-CIAS.aspx
http://www.news-medical.net/news/20130418/FDA-authorizes-SK-Biopharmaceuticals-IND-application-for-SKL15508-to-treat-CIAS.aspx
No comments:
Post a Comment